ClinicalTrials.gg
RecruitingNCT06707090TRIVIAUpdated Feb 12, 2026

Tissue Repair Gel in Venous Leg Ulcers (US)

A Phase 3 interventional study of TR987 0.1% gel + Standard of Care and Standard of care in Venous Leg Ulcer, Venous Ulcer and Venous Stasis Ulcer, sponsored by TR Therapeutics. Recruiting at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by TR Therapeutics · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies in Varicose Ulcer with a site in United States — 33 open to participants now, 43 under way, 4 of them phase 3. Varicose Ulcer · United States.

Planned enrollment
10th of 132
312 · median 53
Started
2025
with 11 others
Phase 3
10 of 155
3 open now
Primary completion
2027-12
later than 38 of 42 live
Registered
137th of 155
by date

Among the 155 studies in Varicose Ulcer with a site in United States, this one is the 10th largest by planned enrollment of the 132 interventional ones that give a count, is one of 12 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 38 of the 42 other live ones, and was the 137th registered.

Varicose Ulcer

370 studies on the registry are indexed under Varicose Ulcer; 74 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

33 of the 155 studies in Varicose Ulcer with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Varicose Ulcer with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.

Read the detailed description

This is an outpatient, randomized, parallel- group, double-blind, multicenter, 16-week study with 2 treatment arms: TR987 0.1% gel + Standard of Care and Standard of Care alone in participants who have a non-healing Venous Leg Ulcer (VLU).

The primary objective is to assess the proportion of participants with Complete Closure of the target ulcer at or before the Week-16 end of treatment (EOT) visit.

Secondary endpoints include: • Proportion of participants with Complete Closure of the target ulcer at or before the Week 16 visit AND for whom the ulcer remains closed at the 3-Month Follow-Up visit after such closure (a composite endpoint). • Change from baseline in participant's perception of pain level at 12 weeks. • Percent change from baseline in the target ulcer area at 12 and 16 weeks. In the event of Complete Closure before these time points, the target ulcer area will be deemed to be zero at those time points for purposes of calculation of this endpoint. • Proportion of participants with Complete Closure of the target ulcer at or before the Week 12 treatment visit. • Proportion of participants with any significant reduction in pain at or before 12 weeks. There are also some supplementary and safety endpoints.

03

Conditions studied

  • Venous Leg Ulcer
  • Venous Ulcer
  • Venous Stasis Ulcer
  • Venous Stasis
  • Wound Heal
  • Wounds
  • Venous Insufficiency of Leg
  • Non-healing Wound

Keywords

  • Tissue Repair
  • Glucoprime
  • TR Therapeutics
  • Debridement
  • VLU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years and older
  • Venous insufficiency has been clinically diagnosed clinically and medically confirmed.
  • Females who are neither pregnant nor breastfeeding and if of are on an acceptable method of .
  • The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.
  • Target ulcer age must be ≥ 4 weeks at Screening.
  • Participants must have adequate arterial flow as confirmed by ABI/TBI, TB, SPP, TCPo2, or Duplex Doppler.
  • (BMI) ≤ 50 kg/m2.
  • ≤12%.

Exclusion criteria

Exclusion Criteria:

  • Target ulcer has been treated with prohibited medications or therapies.
  • History of radiation at the target ulcer site.
  • Target ulcer decreases in area by 30% or more during screening period.
  • History of osteomyelitis at the target ulcer within 6 months of screening.
  • Participants considered nutritionally deficient.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    TR987 0.1% gel + Standard of Care

    Participants will receive up to 16 weeks of TR987 0.1% gel topically + Standard of Care (wound cleansing/dressings and compression bandaging). Treatment will be twice weekly for the first four weeks then weekly for the remaining 12 weeks.

    Drug: TR987 0.1% gel + Standard of Care

  • Other
    Standard of Care

    Other: Standard of care

Interventions

  • DrugTR987 0.1% gel + Standard of Care

    6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)

  • OtherStandard of care

    Standard of Care (wound cleansing/dressings and compression bandaging)

06

What researchers measure

Primary outcomes

  1. Proportion of participants with Complete Closure of the target ulcer at or before the Week-16 end of treatment (EOT) visit.

    Patient count

    Time frame: 16 weeks

Secondary outcomes

  1. Proportion of participants with Complete Closure of the target ulcer at or before the Week 16 visit AND for whom the ulcer remains closed at the 3-Month Follow-Up visit after such closure (a composite endpoint)

    Patient count

    Time frame: 16 weeks

  2. Change from baseline in participant's perception of pain level at 12 weeks.

    Pain to be measured on a 10 point numeric rating scale

    Time frame: 12 weeks

  3. Percent change from baseline in the target ulcer area at 12 and 16 weeks. In the event of Complete Closure before these time points, the target ulcer area will be deemed to be zero at those time points for purposes of calculation of this endpoint.

    Measure the are of the wound in cm2 at baseline and at 12 and 16 weeks and calculate the percentage change

    Time frame: 12 and 16 weeks

  4. Proportion of participants with Complete Closure of the target ulcer at or before the Week 12 treatment visit.

    Count the number of patients with complete closure and divide by the total number of patients

    Time frame: 12 weeks

  5. Proportion of participants with any significant reduction in pain at or before 12 weeks.

    Count the number of patients with any significant reduction in pain and divide by the total number of patients

    Time frame: 12 weeks

  6. Proportion of target ulcers which reach greater than 70% closure at 12 weeks and 16 weeks

    Measured by MolecuLight® versus baseline area at TV1 after therapeutic debridement (Complete Closure at a time point before 12 or 16 weeks shall be deemed to be \>70% closed at 12 or 16-weeks, respectively, for purposes of this analysis)

    Time frame: 12 and 16 weeks

  7. Proportion of target ulcers which reach greater than 90% closure at 12 weeks and 16 weeks

    Measured by MolecuLight® versus baseline area at TV1 after therapeutic debridement (Complete Closure at a time point before 12 or 16 weeks shall be deemed to be \>70% closed at 12 or 16-weeks, respectively, for purposes of this analysis)

    Time frame: 12 and 16 weeks

  8. Proportion of target ulcers which reach greater than 95% closure at 12 weeks and 16 weeks

    Measured by MolecuLight® versus baseline area at TV1 after therapeutic debridement (Complete Closure at a time point before 12 or 16 weeks shall be deemed to be \>70% closed at 12 or 16-weeks, respectively, for purposes of this analysis)

    Time frame: 12 and 16 weeks

07

Study locations

24 of 33 sites recruiting
  • Clincial Research Site 21
    Tucson, Arizona 85715, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clincial Research Site 43C
    Castro Valley, California 94546, United States
    Recruiting
  • Clincial Research Site 14
    Fresno, California 93710, United States
    Recruiting
  • Clincial Research Site 11
    Los Angeles, California 90063, United States
    Recruiting
  • Clincial Research Site 43A
    San Francisco, California 94115, United States
    Recruiting
  • Clincial Research Site 43B
    San Francisco, California 94117, United States
    Recruiting
  • Clincial Research Site 54
    Vista, California 92081, United States
    Recruiting
  • Clincial Research Site 47
    Deerfield Beach, Florida 33442, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clincial Research Site 38
    Hollywood, Florida 33021, United States
    Not yet recruiting
  • Clincial Research Site 40
    Jacksonville, Florida 32209, United States
    Recruiting
  • Clincial Research Site 19
    Miami, Florida 33150, United States
    Recruiting
  • Clincial Research Site 26
    Miami, Florida 33156, United States
    Recruiting
  • Clincial Research Site 13
    Pembrook Pines, Florida 33026, United States
    Recruiting
  • Clincial Research Site 51
    Tamarac, Florida 33321, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clincial Research Site 22
    Chicago, Illinois 60611, United States
    Not yet recruiting
  • Clincial Research Site 34
    Chicago, Illinois 60649, United States
    Recruiting
  • Clincial Research Site 10
    O'Fallon, Illinois 62269, United States
    Recruiting
  • Clincial Research Site 49
    Springfield, Illinois 62704, United States
    Recruiting
  • Clincial Research Site 04
    Bossier City, Louisiana 71111, United States
    Recruiting
  • Clincial Research Site 01
    Lafayette, Louisiana 70507, United States
    Recruiting
  • Clincial Research Site 07
    D'Iberville, Mississippi 39540, United States
    Recruiting
  • Clincial Research Site 02
    McComb, Mississippi 39648, United States
    Recruiting
  • Clincial Research Site 30
    New York, New York 10019, United States
    Recruiting
  • Clincial Research Site 37
    Syosset, New York 11791, United States
    Recruiting
  • Clincial Research Site 55
    Winston-Salem, North Carolina 27157, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clincial Research Site 45
    Grove City, Ohio 43123, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clincial Research Site 23
    Mentor, Ohio 44060, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clincial Research Site 28
    Tulsa, Oklahoma 74137, United States
    Recruiting
  • Clincial Research Site 36
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Clincial Research Site 24
    Fort Worth, Texas 76104, United States
    Recruiting
  • Clincial Research Site 32
    Houston, Texas 27707, United States
    Recruiting
  • Clincial Research Site 46
    San Antonio, Texas 78224, United States
    Not yet recruiting
  • Clincial Research Site 18
    Suffolk, Virginia 23434, United States
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — If the clinical data will be published, the relevant information may be made available.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2024
First posted
Nov 27, 2024
StartActual
Jan 28, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Feb 2028
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06707090
Lead sponsor
TR Therapeutics
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Jan 28, 2025
Primary completion
Dec 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Feb 12, 2026

Study contacts

Anhthu Nguyen Vice President, Global Clinical Operations
Contact
anhthu.nguyen@trtherapeutics.com
(+61) 280 034 554

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion